Anticancer efficacy of the metabolic blocker 3-bromopyruvate: Specific molecular targeting

Anticancer Research

Volumn 33, Issue 1, 2013, Pages 13-20

  Ganapathy Kanniappan, Shanmugasundaram ^a   Kunjithapatham, Rani ^a   Geschwind, Jean Francois ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 Bromopyruvate; GAPDH; Glucose metabolism; Glycolysis; HCC; Locoregional therapy; Molecular targeting; Review

Indexed keywords

ALKYLATING AGENT; BROMOPYRUVIC ACID; DAUNORUBICIN; DEOXYGLUCOSE; FLUOROURACIL; GLYCERALDEHYDE 3 PHOSPHATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LACTATE DEHYDROGENASE; MITOXANTRONE; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BRAIN TOXICITY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; ENDOPLASMIC RETICULUM STRESS; ENERGY METABOLISM; ENZYME ACTIVITY; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; MOLECULARLY TARGETED THERAPY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ENZYME INHIBITORS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; MOLECULAR TARGETED THERAPY; MONOCARBOXYLIC ACID TRANSPORTERS; NEOPLASMS; PYRUVATES;

EID: 84873027161     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Tang S, Huang G, Liu J, Liu T, Treven L, Song S, Zhang C, Pan L and Zhang T: Usefulness of 18F-FDG-PET, combined FDGPET/ CT and EUS in diagnosing primary pancreatic carcinoma: A meta-analysis. Eur J Radiol 78(1): 142-150, 2011.
2. Annibaldi A and Widmann C: Glucose metabolism in cancer cells. Curr Opin Clin Nutr Metab Care 13(4): 466-470, 2010.
3. Madhok BM, Yeluri S, Perry SL, Hughes TA and Jayne DG: Targeting glucose metabolism: An emerging concept for anticancer therapy. Am J Clin Oncol 34(6): 628-635, 2011.
4. Dang CV: Links between metabolism and cancer. Genes Dev 26(9):877-890, 2012.
5. Dwarakanath B and Jain V: Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol 5(5): 581-585, 2009.
6. Pelicano H, Martin DS, Xu RH and Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 25(34): 4633-4646, 2006.
7. Fantin VR, St-Pierre J and Leder P: Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9(6): 425-434, 2006.
8. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL and Dang CV: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107(5): 2037-2042, 2010.
9. Cardaci S, Rizza S, Filomeni G, Bernardini R, Bertocchi F, Mattei M, Paci M, Rotilio G and Ciriolo MR: Glutamine deprivation enhances antitumor activity of 3-bromopyruvate through the stabilization of monocarboxylate transporter-1. Cancer Res 72(17): 4526-4536, 2012.
10. Hamanaka RB and Chandel NS: Targeting glucose metabolism for cancer therapy. J Exp Med 209(2): 211-215, 2012.
11. Ko YH, Pedersen PL and Geschwind JF: Glucose catabolism in the rabbit VX2 tumor model for liver cancer: Characterization and targeting hexokinase. Cancer Lett 173(1): 83-91, 2001.
12. Geschwind JF, Ko YH, Torbenson MS, Magee C and Pedersen PL: Novel therapy for liver cancer: Direct intra-arterial injection of a potent inhibitor of ATP production. Cancer Res 62(14): 3909-3913, 2002.
13. Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, Almeida FC, Da Poian AT and Galina A: Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 417(3): 717-726, 2009.
14. Ganapathy-Kanniappan S, Geschwind J, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Torbenson MS, Cole RN, Syed LH and Vali M: A pyruvic acid analog primarily targets GAPDH to promote cancer cell death. FASEB J 23(1-MeetingAbstracts): 678.2, 2009.
15. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Cole RN, Syed LH, Rao PP, Ota S and Vali M: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate-mediated cancer cell death. Anticancer Res 29(12): 4909-4918, 2009.
16. Tang Z, Yuan S, Hu Y, Zhang H, Wu W, Zeng Z, Yang J, Yun J, Xu R and Huang P: Overexpression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester. J Bioenerg Biomembr 44(1): 117-125, 2012.
17. Ihrlund LS, Hernlund E, Khan O and Shoshan MC: 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol 2(1): 94-101, 2008.
18. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R and Vali M: 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Res 30(3): 923-935, 2010.
19. Ganapathy-Kanniappan S, Kunjithapatham R, Torbenson MS, Rao PP, Carson KA, Buijs M, Vali M and Geschwind JF: Human hepatocellular carcinoma in a mouse model: Assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists. Radiology 262(3): 834-845, 2012.
20. Lemma T and Pawliszyn J: Human serum albumin interaction with oxaliplatin studied by capillary isoelectric focusing with the whole column imaging detection and spectroscopic method. J Pharm Biomed Anal 50(4): 570-575, 2009.
21. Groessl M, Terenghi M, Casini A, Elviri L, Lobinski R and Dyson PJ: Reactivity of anticancer metallodrugs with serum proteins: New insights from size exclusion chromatography-ICPMS and ESI-MS. J Anal At Spectrom 25(3): 305-313, 2010.
22. Singal PK and Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13): 900-905, 1998.
23. Giri SN, Al-Bayati MA, Du X, Schelegle E, Mohr FC and Margolin SB: Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol 53(2): 141-150, 2004.
24. Vali M, Vossen JA, Buijs M, Engles JM, Liapi E, Ventura VP, Khwaja A, Acha-Ngwodo O, Shanmugasundaram G, Syed L, Wahl RL and Geschwind JF: Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: A biodistribution and survival study. J Pharmacol Exp Ther 327(1): 32-37, 2008.
25. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC and Baltazar F: Role of monocarboxylate transporters in human cancers: State of the art. J Bioenerg Biomembr 44(1): 127-139, 2012.
26. de Oliveira AT, Pinheiro C, Longatto-Filho A, Brito MJ, Martinho O, Matos D, Carvalho AL, Vazquez VL, Silva TB, Scapulatempo C, Saad SS, Reis RM and Baltazar F: Coexpression of monocarbo-xylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J Bioenerg Biomembr 44(1): 171-178, 2012.
27. Thangaraju M, Karunakaran SK, Itagaki S, Gopal E, Elangovan S, Prasad PD and Ganapathy V: Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer 115(20): 4655-4666, 2009.
28. Matsumoto S, Saito K, Yasui H, Morris HD, Munasinghe JP, Lizak M, Merkle H, Ardenkjaer-Larsen JH, Choudhuri R, Devasahayam N, Subramanian S, Koretsky AP, Mitchell JB and Krishna MC: EPR oxygen imaging and hyperpolarized (13) C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate Magn Reson Med. 2012 Jun 12. doi: 10.1002/mrm.24355. [Epub ahead of print].
29. Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B, Hall NC, Koch RM, Cheng H, Knopp MV and Sun D: Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res 14(6): 1831-1839, 2008.
30. Cao X, Jia G, Zhang T, Yang M, Wang B, Wassenaar PA, Cheng H, Knopp MV and Sun D: Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. Cancer Chemother Pharmacol 62(6): 985-994, 2008.
31. Filomeni G, Cardaci S, Da Costa Ferreira AM, Rotilio G and Ciriolo MR: Metabolic oxidative stress elicited by the copper (II) complex [Cu(isaepy)2] triggers apoptosis in SH-SY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signaling axis: Evidence for a combined use with 3-bromopyruvate in neuroblastoma treatment. Biochem J 437(3): 443-453, 2011.
32. Yu SJ, Yoon JH, Lee JH, Myung SJ, Jang ES, Kwak MS, Cho EJ, Jang JJ, Kim YJ and Lee HS: Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. Acta Pharmacol Sin 32(7): 912-920, 2011.
33. El Sayed SM, Abou El-Magd RM, Shishido Y, Chung SP, Sakai T, Watanabe H, Kagami S and Fukui K: D-Amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate. Cancer Gene Ther 19(1): 1-18, 2012.
34. Yu SJ, Yoon JH, Yang JI, Cho EJ, Kwak MS, Jang ES, Lee JH, Kim YJ, Lee HS and Kim CY: Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and antiangiogenesis by protein disulfide isomerase inhibition. J Bioenerg Biomembr 44(1): 101-115, 2012.
35. Wintzell M, Lofstedt L, Johansson J, Pedersen AB, Fuxe J and Shoshan M: Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate Cancer Biol Ther 13(14): 2012.
36. Nakano A, Tsuji D, Miki H, Cui Q, El Sayed SM, Ikegame A, Oda A, Amou H, Nakamura S, Harada T, Fujii S, Kagawa K, Takeuchi K, Sakai A, Ozaki S, Okano K, Nakamura T, Itoh K, Matsumoto T and Abe M: Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One 6(11): e27222, 2011.
37. Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J, Gao G, Zhang A, Xia X, Brasher H, Widger W, Ellis LM and Weihua Z: Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res 72(1): 304-314, 2012.